Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Michelle Rudek"'
Autor:
Emerson Lee, Jonathan Coulter, Alok Mishra, Fernanda Caramella-Pereira, Angelo Demarzo, Michelle Rudek, Chen Hu, Misop Han, Theodore L. DeWeese, Srinivasan Yegnasubramanian, Daniel Y. Song
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background Prostate cancer remains the most prevalent malignancy and the second-leading cause of cancer-related death in men in the USA. Radiation therapy, typically with androgen suppression, remains a mainstay in the treatment of intermedi
Externí odkaz:
https://doaj.org/article/71ec43ee178046758617d9ad5dd582f8
Autor:
Eudocia Lee, Michelle Rudek, Veronica Rendo, Nicholas Khuu, Tobias Walbert, Matthias Holdhoff, Frank Lieberman, Arati Desai, Roy Strowd, Emily Lapinskas, Kristine Pelton, William Pisano, Serena Desideri, Neeraja Danda, Joy Fisher, Xiaobu Ye, L Burt Nabors, Stuart Grossman, Rameen Beroukhim, Brian Alexander, Keith Ligon, Patrick Y Wen
Publikováno v:
Neuro-Oncology. 24:vii76-vii76
BACKGROUND KRT232 is an orally bioavailable, selective small molecule inhibitor of MDM2 that blocks the protein-protein interaction between MDM2 and p53. We performed a surgical window of opportunity trial of KRT232 in patients with recurrent GBM. ME
Autor:
Karisa Schreck, Roy Strowd, L Burt Nabors, Ben Ellingson, Joy Fisher, Serena Desideri, Neeraja Danda, Michelle Rudek, Stuart Grossman, Xiaobu Ye
Publikováno v:
Neuro-Oncology. 24:vii86-vii86
BACKGROUND Although < 5% of high-grade gliomas (HGG) are BRAF-V600E mutated, these tumors are being identified more frequently as genetic testing increases in gliomas. Given the treatment-refractory nature HGG, RAF-targeted therapy is of special inte
Autor:
Missak Haigentz, Page Moore, Milan Bimali, Timothy Cooley, Joseph Sparano, Michelle Rudek, Lee Ratner, David Henry, Juan Ramos, John Deeken, Paul Rubinstein, Elizabeth Chiao
Publikováno v:
The oncologist. 27(8)
Background Persons living with human immunodeficiency virus are an underserved population for evidence-based cancer treatment. Paclitaxel and carboplatin (PCb) is an active regimen against a variety of solid tumors, including several seen in excess i
Autor:
Susan E Krown, Carlee B Moser, Patrick MacPhail, Roy M Matining, Catherine Godfrey, Stephanie R Caruso, Mina C Hosseinipour, Wadzanai Samaneka, Mulinda Nyirenda, Naftali W Busakhala, Fred M Okuku, Josphat Kosgei, Brenda Hoagland, Noluthando Mwelase, Vincent O Oliver, Henriette Burger, Rosie Mngqibisa, Mostafa Nokta, Thomas B Campbell, Margaret Z Borok, Agnes Moses, Cecilia Kanyama, Pamela Mukwekwerere, Ivy Gudza, Felluna Chauwa, Godwin Ulaya, Irene Kutto, Priscilla Cheruiyot, Clement Okello, Annet Nakaganda, Geoffrey Koskei, Winnie Keter, Juliana Netto, Tamiris Baião, Iveshni Govender, Jessica O'Connell-Maritz, Kevin Cain, John Okanda, Lynne Cornelissen, Marije Van Schalkwyk, Rejoice Sikhosana, Minenhle Ngcobo, Jeannette Y. Lee, Taylor Harrison, William Wachsman, Katherine Shin, Scott Evans, Jennifer Rothenberg, Lara Hosey, Sean McCarthy, Otoniel Martinez-Maza, Charles Rinaldo, Dirk Dittmer, Courtney Fletcher, Michelle Rudek, Aida Asmelash, Valery Hughes, Jeffrey Schouten, David Shugarts, Tapiwanashe Kujinga, Amanda Zadzilka, Fredrick Kerui, Debora Robertson, James Rooney, Krishna Sewal, Brian Gottshall
Publikováno v:
The Lancet. 395:1195-1207
Summary Background Optimal treatment regimens for AIDS-associated Kaposi sarcoma, a frequent contributor to morbidity and mortality among people with HIV, have not been systematically evaluated in low-income and middle-income countries, where the dis
Autor:
Abhijit A, Date, Max, Kates, Takahiro, Yoshida, Taarika, Babu, Umara, Afzal, Pranjali, Kanvinde, Alexander, Baras, Nicole, Anders, Ping, He, Michelle, Rudek, Justin, Hanes, Trinity J, Bivalacqua, Laura M, Ensign
Publikováno v:
Drug delivery and translational research. 11(5)
Intravesical chemotherapy is a key approach for treating refractory non-muscle-invasive bladder cancer (NMIBC). However, the effectiveness of intravesical chemotherapy is limited by bladder tissue penetration and retention. Here, we describe the deve
Autor:
Michelle Rudek-Renaut, Stuart A. Grossman, Joy D. Fisher, Patrick Y. Wen, Burt Nabors, Jeffrey G. Supko, Carlos G Romo, Xiaobu Ye, David M. Peereboom, Benjamin M. Ellingson
Publikováno v:
Neuro Oncol
Despite advances in the understanding of molecular pathways, the availability of NGS panels to identify potentially drugable mutations, the proliferation of targeted therapies, and the progress seen in other cancers, only one novel agent (temozolomid
Autor:
Rosalyn A. Juergens, John Wrangle, Charles M. Rudin, James G. Herman, Barbara Coleman, Rosa Sebree, Steven A. Belinsky, Malcolm V. Brock, Stephen B. Baylin, Michelle Rudek-Renaut, Frank P. Vendetti
Publikováno v:
Cancer Research. 71:LB-411
Background: Epigenetic gene silencing is a key contributor to carcinogenesis. Pre-clinical studies suggest that combined inhibition of DNA methyltransferase and of histone deacetylase activity can synergistically re-express aberrantly silenced genes.